A pioneering leader in histone deacetylase inhibitor research, focusing on largazole analogs.
Cetya Therapeutics, Inc. (“Cetya”) was formed in 2012 to commercialize histone deacetylase inhibitors (HDACi) based on largazole. Some of these analogs have bifunctional modifications and the potential to target specific cell types or tumors. This is unique...More
Collaborations are an important component for any early stage company, particularly one like Cetya. Cetya has multiple potential therapeutic candidates in a variety of clinical indications. Cetya is seeking to collaborate with academic scientists or potentia...More